(Q40554971)

English

High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast can

scientific article published on August 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast can (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

1

object named as

U De Giorgi

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

G Rosti

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A Zaniboni

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

M Ballardini

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

M R Minzi

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

M Baioni

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

E Ferrari

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

L Zornetta

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

M Marangolo

9

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

251-255

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704125

0 references

Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

21 January 2018

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose response in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704125

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704125

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40554971&oldid=2092451744"